Virpax Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Virpax Pharmaceuticals (NASDAQ: VRPX), a company focused on pain management and CNS disorders, announced its participation in the H.C. Wainwright Global Investment Conference from May 24 to May 27. Chairman & CEO Anthony P. Mack will present on-demand starting at 7:00 a.m. ET. Additionally, one-on-one virtual meetings will be available from May 25 to May 27. A replay of the presentation can be accessed for 90 days on the Virpax website. The company is developing innovative pain management products, including Epoladerm™, Probudur™, and Envelta™.

BERWYN, Pa.--(BUSINESS WIRE)-- Virpax^® Pharmaceuticals, Inc. (“Virpax”) (NASDAQ: VRPX), a company specializing in product candidates for pain management, CNS disorders and anti-viral indications, today announced that it will be presenting virtually at the upcoming H.C. Wainwright event from Tuesday, May 24^th starting at 7:00 a.m. ET through Friday, May 27^th. Anthony P. Mack, Chairman & CEO of Virpax, will be giving the presentation. Management will also be hosting virtual one-on-one meetings on Wednesday, May 25^th through Friday, May 27^th.

Event: Virpax Pharma Virtual Presentation at the H.C. Wainwright Global Investment Conference
Date: Tuesday, May 24^th through Friday, May 27th
Time: On Demand starting at 7:00 a.m. ET
Webcast: Register Here

A replay of the presentation will also be available for 90 days on the Virpax website.

For more information on the H.C. Wainwright Global Investment Conference or to schedule a one-on-one meeting with Virpax management, please contact your conference representative or you may also email your request to betsy.brod@affinitygrowth.com or call (212) 661-2231.

About Virpax Pharmaceuticals

Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval for three drugs that employ three different patented drug delivery platforms. Epoladerm™ is a topical diclofenac metered-dose spray film formulation being developed to manage acute musculoskeletal pain and osteoarthritis. Probudur™ is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta™ is an intranasal molecular-envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. Virpax is also using its intranasal Molecular Envelope Technology (MET) to develop two other products, its PES200 product candidate to manage post-traumatic stress disorder (PTSD) and its AnQlar product candidate to inhibit viral replication caused by influenza or SARS-CoV-2. For more information, please visit www.virpaxpharma.com.

About H.C. Wainwright & Co.

H.C. Wainwright is a full‐service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright’s team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220519005105/en/

Christopher M. Chipman, CPA

Chief Financial Officer

cchipman@virpaxpharma.com

(610) 727-4597



Or



Investor Relations:

Betsy Brod

Affinity Growth Advisors

betsy.brod@affinitygrowth.com

(212) 661-2231



Media:

Laura Radocaj

DGI

212-825-3210

Source: Virpax Pharmaceuticals, Inc.

FAQ

When is the Virpax Pharmaceuticals presentation at the H.C. Wainwright event?

The presentation is scheduled from May 24 to May 27, 2022.

What time will the Virpax presentation be available?

The presentation will start on-demand at 7:00 a.m. ET.

Who will present for Virpax Pharmaceuticals?

Chairman & CEO Anthony P. Mack will deliver the presentation.

How can I access the replay of the Virpax presentation?

The replay will be available for 90 days on the Virpax website.

What products is Virpax Pharmaceuticals developing?

Virpax is developing Epoladerm™, Probudur™, and Envelta™ for pain management.

How can I schedule a one-on-one meeting with Virpax management?

You can contact your conference representative or email bets.brod@affinitygrowth.com.